Skip to main content
Premium Trial:

Request an Annual Quote

Foundation Medicine, Novartis Partner on Cancer Diagnostic

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pharmacogenomic test development firm Foundation Medicine today announced a collaboration with Novartis to develop, enhance, and optimize Foundation's cancer genome panel test.

The deal is Foundation's first with a drug firm, and if the pilot phase is successful the two companies will evaluate opportunities to commercialize the test.

"By delivering a clinical-grade analysis of molecular information, Foundation's dedicated clinical research team will help our partners more rapidly translate novel findings into therapeutically applicable results," Alexis Borisy, CEO of Cambridge, Mass.-based Foundation, said in a statement. "This collaboration is an important step forward for Foundation and could provide us with the basis for building successful cancer genome analysis platforms for future collaborations and partners."

Financial and other terms of the deal were not disclosed.

Privately-held Foundation raised $25 million in a Series A round of financing last April.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.